Neuromed Pharmaceuticals Ltd.

Canada

Back to Profile

1-10 of 10 for Neuromed Pharmaceuticals Ltd. Sort by
Query
Aggregations
IPC Class
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin 5
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol 3
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine 2
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms 2
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links 2
See more
Found results for  patents

1.

SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS

      
Application Number US2008011286
Publication Number 2009/045382
Status In Force
Filing Date 2008-09-30
Publication Date 2009-04-09
Owner
  • MERCK SHARP & DOHME CORP. (USA)
  • NEUROMED PHARMACEUTICALS LTD. (Canada)
Inventor
  • Chakravarty, Prasun, K.
  • Ding, Yanbing
  • Duffy, Joseph, L.
  • Pajouhesh, Hassan
  • Shao, Pengcheng Patrick
  • Tyagarajan, Sriram
  • Ye, Feng

Abstract

A series of substituted aryl sulfone derivatives represented by Formula I, or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, calcium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, urinary incontinence, itchiness, allergic dermatitis, epilepsy, diabetic neuropathy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, sleep disorder, bipolar disorder and stroke, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds.

IPC Classes  ?

  • A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
  • A61K 31/445 - Non-condensed piperidines, e.g. piperocaine

2.

AMINO ACID DERIVATIVES AS CALCIUM CHANNEL BLOCKERS

      
Application Number CA2008000962
Publication Number 2008/141446
Status In Force
Filing Date 2008-05-16
Publication Date 2008-11-27
Owner NEUROMED PHARMACEUTICALS LTD. (Canada)
Inventor
  • Galemmo, Robert, Jr.
  • Holland, Richard
  • Ding, Yanbing
  • Zhang, Lingyun
  • Hum, Gabriel
  • Chahal, Navjot
  • Duffy, Joseph
  • Stevenson, Christian
  • Ullman, Andrew

Abstract

Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type and/or T-type calcium channel activity are disclosed. Specifically, a series of compounds containing both an amino acid functionality and multiple aromatic rings are disclosed of the general formula (1) where X is benzhydryl, or an aromatic or heteroaromatic ring.

IPC Classes  ?

  • A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
  • A61K 31/277 - NitrilesIsonitriles having a ring, e.g. verapamil
  • A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof

3.

BICYCLIC PYRIMIDINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS

      
Application Number CA2008000904
Publication Number 2008/138126
Status In Force
Filing Date 2008-05-08
Publication Date 2008-11-20
Owner NEUROMED PHARMACEUTICALS LTD. (Canada)
Inventor
  • Pajouhesh, Hassan
  • Pajouhesh, Hossein
  • Ding, Yanbing
  • Tan,jason
  • Grimwood, Mike
  • Belardetti, Francesco
  • Kaul, Ramesh

Abstract

Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted T-type calcium channel activity are disclosed. Specifically, a series of compounds containing thienopyrimidine or oxoquinazoline derivatives are disclosed of the general formula (1) or formula (2) where X is a linker and Y is an aromatic moiety or N(R5)(R6).

IPC Classes  ?

  • A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
  • A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol

4.

AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS

      
Application Number CA2008000490
Publication Number 2008/110008
Status In Force
Filing Date 2008-03-12
Publication Date 2008-09-18
Owner NEUROMED PHARMACEUTICALS LTD. (Canada)
Inventor
  • Pajouhesh, Hassan
  • Zhou, Yuanxi
  • Chakka, Nagasree
  • Belardetti, Francesco

Abstract

Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted T-type calcium channel activity are disclosed. Specifically, a series of compounds containing both a diamide and aromatic functionality are disclosed of the general formula (I) where X1 and X2 are linkers.

IPC Classes  ?

  • C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
  • A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
  • A61K 31/4468 - Non-condensed piperidines, e.g. piperocaine having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl
  • A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
  • A61P 25/04 - Centrally acting analgesics, e.g. opioids
  • A61P 25/08 - AntiepilepticsAnticonvulsants
  • A61P 9/00 - Drugs for disorders of the cardiovascular system
  • C07C 237/24 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
  • C07D 209/14 - Radicals substituted by nitrogen atoms, not forming part of a nitro radical
  • C07D 211/66 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4

5.

CYCLOPROPYL-PIPERAZINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS

      
Application Number CA2007001827
Publication Number 2008/043183
Status In Force
Filing Date 2007-10-12
Publication Date 2008-04-17
Owner NEUROMED PHARMACEUTICALS LTD. (Canada)
Inventor
  • Pajouhesh, Hassan
  • Pajouhesh, Hossein
  • Kaul, Ramesh

Abstract

Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type calcium channel activity are disclosed. Specifically, a series of compounds containing both a piperazine ring and a cyclopropyl ring are disclosed of the general formula (I) where X1 and X2 are linkers.

IPC Classes  ?

  • C07D 295/182 - Radicals derived from carboxylic acids
  • A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
  • A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
  • A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
  • C07D 401/08 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
  • C07D 403/08 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing alicyclic rings
  • C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 413/08 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
  • C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

6.

DIARYL PIPERIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS

      
Application Number CA2007001638
Publication Number 2008/031227
Status In Force
Filing Date 2007-09-14
Publication Date 2008-03-20
Owner NEUROMED PHARMACEUTICALS LTD. (Canada)
Inventor
  • Pajouhesh, Hassan
  • Ding, Yanbing
  • Pajouhesh, Hossein
  • Holland, Richard
  • Hum, Gabriel

Abstract

Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type calcium channel activity are disclosed. Specifically, a series of diaryl piperidine compounds are disclosed of the general formula (I) where X is a linker and Y may be C, O, S or N.

IPC Classes  ?

  • C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
  • A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
  • A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
  • A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
  • C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
  • C40B 40/04 - Libraries containing only organic compounds

7.

HETEROCYCLIC COMPOUNDS AS CALCIUM CHANNEL BLOCKERS

      
Application Number CA2007000943
Publication Number 2007/137417
Status In Force
Filing Date 2007-05-25
Publication Date 2007-12-06
Owner NEUROMED PHARMACEUTICALS LTD. (Canada)
Inventor
  • Pajouhesh, Hassan
  • Ding, Yanbing

Abstract

Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type calcium channel activity are disclosed. Specifically, a series of heterocyclic compounds are disclosed of the general formula (1) where X1 and X2 are linkers and W is an optionally substituted imidazolyl, oxazolyl, thiazolyl, benzimidazolyl, benzoxazolyl, or benzothiazolyl.

IPC Classes  ?

  • C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
  • A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
  • A61P 3/14 - Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
  • C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

8.

METHOD FOR INCREASING THE BIOAVAILABILITY OF BENZHYDRYL PIPERAZINE CONTAINING COMPOUNDS

      
Application Number US2007010846
Publication Number 2007/133481
Status In Force
Filing Date 2007-05-04
Publication Date 2007-11-22
Owner NEUROMED PHARMACEUTICALS LTD. (Canada)
Inventor
  • Snutch, Terrance, P.
  • Fisher, Dennis, M.

Abstract

A method of increasing the bioavailability of a compound of formula (1) by orally administering to a patient a compound of formula (1), or a pharmaceutically acceptable salt thereof, with food.

IPC Classes  ?

9.

ISOXAZOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS

      
Application Number CA2007000632
Publication Number 2007/118323
Status In Force
Filing Date 2007-04-17
Publication Date 2007-10-25
Owner NEUROMED PHARMACEUTICALS LTD. (Canada)
Inventor
  • Pajouhesh, Hassan
  • Holland, Richard
  • Pajouhesh, Hossein

Abstract

Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type or T-type calcium channel activity are disclosed. Specifically, a series of isoxazole containing compounds are disclosed of the general formula (1) where Z is N or CHNR3 and (Ar1)2CR4 is optionally substituted benzhydryl.

IPC Classes  ?

  • C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
  • A61K 31/42 - Oxazoles
  • A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
  • C07D 261/08 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
  • C07D 261/18 - Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen

10.

HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS

      
Application Number CA2006002070
Publication Number 2007/071035
Status In Force
Filing Date 2006-12-19
Publication Date 2007-06-28
Owner NEUROMED PHARMACEUTICALS LTD. (Canada)
Inventor
  • Pajouhesh, Hassan
  • Kaul, Ramesh
  • Ding, Yanbing
  • Hum, Gabriel
  • Pajouhesh, Hossein

Abstract

Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type or T-type calcium channel activity are disclosed. Specifically, a series of heterocyclic amides are disclosed of the general formula (I) where Z is N or CHNR2 and X is NR2, O, S, S=O or SO2. Among other definitions for R, R1, W and Y, the compounds of formula (1) are further characterized by at least one of W or Y being CR3Ar2 where Ar is an aromatic or heteroaromatic ring (for example, where W or Y is a benzhydryl moiety).

IPC Classes  ?

  • C07D 295/185 - Radicals derived from carboxylic acids from aliphatic carboxylic acids
  • A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
  • A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
  • C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
  • C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms